There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LTA4H


LTA4H Molecule Information

Name:Leukotriene A-4 hydrolase
Target Synonym:LTA4;LTA4H;Leukotriene A-4 hydrolase;Leukotriene A(4) hydrolase;LTA-4 hydrolase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

LTA4H Molecule Synonym Name


LTA4H Molecule Background

Leukotriene A4 hydrolase (LTA4H) is a protein which belongs to the peptidase M1 family, specifically those acting on ether bonds (ether hydrolases). LTA4H is bifunctional enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTA4H participates in arachidonic acid metabolism. LTA4H is inhibited by bestatin and subject to suicide inhibition by leukotriene A4, due to the formation of a covalent adduct at Tyr-379. LTA4H binds 1 zinc ion per subunit.

LTA4H References

LTA4H Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ubenimex NK-421; NSC-265489; 1580RB Approved Nippon Kayaku, Eiger BioPharmaceuticals Ubenimex Tablets cfda Acute myeloid Leukemia (AML), Cancer chemotherapy 2014-11-17 Lymphoblastic leukaemia Details

LTA4H Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JNJ-40929837 JNJ-40929837 Phase Ⅱ Johnson & Johnson Asthma Details
BI-691751 BI-691751 Phase Ⅰ Boehringer Ingelheim Atherosclerosis Details
DG-051 DG-051,DG051 Phase Ⅱ Amgen Myocardial infarction (MI) Details
JNJ-27265732 Preclinical Johnson & Johnson Atopic dermatitis, Inflammatory bowel disease, Asthma Details
Acebilustat CTX-4430; EP-501 Phase Ⅱ Celtaxsys Cystic fibrosis (CF) Details

This web search service is supported by Google Inc.